PressOctober 7, 2024 Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
PressOctober 7, 2024 Filament Health Announces Issuance of Common Shares to Negev Capital Investments Limited Pursuant to Advisory Agreement
PressOctober 4, 2024 Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
PressOctober 4, 2024 Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
PressOctober 2, 2024 Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
PressSeptember 30, 2024 Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
PressSeptember 25, 2024 Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
PressSeptember 25, 2024 Red Light Holland Announces NCIB Update and Live Q&A with CEO Todd Shapiro and CFO Jon Szczur on September 26th
PressSeptember 25, 2024 MindBio Therapeutics Enrolls 25th Participant into Landmark Take-Home Microdosing Depression Trial
PressSeptember 25, 2024 Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
PressSeptember 19, 2024 PharmaDrug’s Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PressSeptember 18, 2024 Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
PressSeptember 18, 2024 Psyence Group’s NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
PressSeptember 18, 2024 Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
PressSeptember 16, 2024 Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
PressSeptember 16, 2024 Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
PressSeptember 12, 2024 Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
